The first participant has been enrolled in a large Italian clinical trial that’s testing Avextra’s cannabis-based medicine for managing…
Michela Luciano, PhD
Michela Luciano is a Science Writer at BioNews. Originally from the picturesque mountain town of L’Aquila, Italy, Michela holds a PhD in Molecular Biology from the University of Salzburg. Her research focused on the role of inflammation in acute myeloid leukemia. With a deep passion for scientific communication, Michela transitioned into her first role as Scientific Writer in 2022. Outside of work she enjoys street photography, mountain hikes, running, and spending as much time as possible outdoors.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Michela Luciano, PhD
Researchers in the U.S. and Europe have identified a number of novel blood and spinal fluid biomarkers that could help…
The U.S. Food and Drug Administration (FDA) has granted orphan drug status to CK0803, a regulatory T-cell therapy being developed…
Five students from across Canada whose lives have been directly affected by amyotrophic lateral sclerosis (ALS) received scholarships to…
Far-field potentials (FFPs), weak electrical signals triggered by nerve stimulation that can be recorded noninvasively on the skin, may serve…
Full randomization is nearly complete in the Phase 2/3 COMBAT-ALS trial testing MN-166 (ibudilast) for the treatment of…
A new treatment approach that noninvasively delivers gentle electrical stimulation to the spinal cord and peripheral nerves — the nerves…
Klotho Neurosciences is advancing KLTO‑202, its gene therapy candidate for amyotrophic lateral sclerosis (ALS), to the manufacturing and…
Clinicians view early access to palliative care as beneficial for people with amyotrophic lateral sclerosis (ALS), yet its integration…
The U.S. Food and Drug Administration (FDA) has given Xellsmart Biopharmaceutical the go-ahead to start a Phase 1 clinical…